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424 Contemporary ReviewsA typical hemolytic uremic syndrome (aHUS) presents similarly to thrombotic thrombocytopenic
purpura (TTP) and other causes or conditions with thrombotic microangiopathy (TMA), such as
disseminated intravascular coagulation or sepsis. Similarity in clinical presentation may hinder
diagnosis and optimal treatment selection in the urgent setting in the ICU. However, there is
currentlynoconsensuson thediagnosis or treatmentofaHUSfor ICUspecialists. This reviewaims
to summarize available data on the diagnosis and treatment strategies of aHUS in the ICU to
enhance the understanding of aHUS diagnosis and outcomes in patients managed in the ICU. To
this end, a reviewof the recent literature (January2009-March2016)wasperformed to select the
most relevant articles for ICU physicians. Based on the paucity of adult aHUS cases overall and
within the ICU, no speciﬁc recommendations could be formally graded for the critical care setting.
However, we recognize a core set of skills required by intensivists for diagnosing and managing
patients with aHUS: recognizing thrombotic microangiopathies, differentiating aHUS from
related conditions, recognizing involvement of other organ systems, understanding the
pathophysiology of aHUS, knowing the diagnostic workup and relevant outcomes in critically ill
patients with aHUS, and knowing the standard of care for patients with aHUS based on available
data and guidelines. In conclusion, managing critically ill patients with aHUS requires basic skills
that, in theabsenceof sufﬁcient data frompatients treatedwithin the ICU, canbegleaned froman
increasingly relevant literature outside the ICU. More data on critically ill patients with aHUS are
needed to validate these conclusions within the ICU setting. CHEST 2017; 152(2):424-434
KEY WORDS: atypical hemolytic uremic syndrome; eculizumab; intensive care; organ failure; plasma
exchange; thrombocytopenia; thrombotic microangiopathypical hemolytic uremic syndrome; C3 =
HUS = hemolytic uremic syndrome;
g Escherichia coli; STEC-HUS = Shiga
remic syndrome; TMA = thrombotic
botic thrombocytopenic purpura
ical Intensive Care Unit (Dr Azoulay),
nce; the Medical University of Vienna
ospital, Vienna, Austria; the Virgen de
(Dr Garnacho-Montero), Seville, Spain;
ulty of Medicine (Dr Rusinova), Charles
ublic; the National Research Center for
sia; the University Hospital of Lausanne
Switzerland; the Fattouma Bourguiba
(Dr Abroug), Tunisia; the Ghent
), Ghent, Belgium; the Uniklinik (Dr von
Bergwelt-Baildon), Cologne, Germany; the King’s College Hospital (Dr
Wendon), London, England; and the University College London (Dr
Scully), London, England.
CORRESPONDENCE TO: Elie Azoulay, MD, PhD, Medical Intensive
Care Unit, Hôpital Saint-Louis, ECSTRA team, Biostatistics and
Clinical Epidemiology, UMR 1153 (Center of Epidemiology and
Biostatistics, Sorbonne Paris Cité, CRESS), INSERM, Paris Diderot
Sorbonne University, 1 Ave Claude Vellefaux, 75010 Paris, France;
e-mail: elie.azoulay@sls.aphp.fr
Copyright  2017 The Authors. Published by Elsevier Inc
under license from the American College of Chest Physicians. This is
an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
DOI: http://dx.doi.org/10.1016/j.chest.2017.03.055
in Critical Care Medicine [ 1 5 2 # 2 CHES T A UGU S T 2 0 1 7 ]
Thrombotic microangiopathies (TMAs) are a group of
disorders characterized by thrombocytopenia,
microangiopathic hemolytic anemia, and organ
dysfunction, in which ischemic organ injury can occur
to the brain, kidneys, heart, pancreas, liver, lungs, eyes,
and skin. Conditions occurring with TMAs include
hemolytic uremic syndromes (HUSs) and thrombotic
thrombocytopenic purpura (TTP), and a number of
differential diagnoses that must also be excluded
(Fig 1).1 These conditions have a similar clinical
presentation of consumptive thrombocytopenia,
mechanical hemolysis, and organ failure, but with
distinct causes, and are typically associated with
thickening and inﬂammation of arterioles and
capillaries, detachment and swelling of endothelial cells,
subendothelial widening, accumulation of proteins and
cellular debris, or platelet thrombi that obstruct the
vascular lumen.1,2
Herein, we will focus on one of these conditions, atypical
hemolytic uremic syndrome (aHUS). aHUS is a rare but
life-threatening condition that affects both children andTT
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chestjournal.orgadults. It accounts for approximately 10% of cases of
HUS in children, but most HUS cases in adults.3 The
annual incidence of aHUS is thought to be around 1 to 2
per million in adults4; however, epidemiologic data are
limited.5 aHUS is distinct from typical, or diarrhea-
associated, HUS, now commonly called Shiga toxin-
associated hemolytic uremic syndrome (STEC-HUS),
which is typically caused by Shiga toxin because of
bacterial infection and often associated with bloody
diarrhea. In most cases, aHUS is caused by the
uncontrolled activation of the complement system,
which leads to platelet, leucocyte, and endothelial cell
activation and TMA,1,6-8 ultimately causing thrombosis
and organ dysfunction.8,9 Accordingly, it may be
unmasked by conditions with enhanced complement
activation, such as systemic lupus erythematosus,
pregnancy, malignant hypertension, and hematopoietic
stem cell transplantation.
Genetic abnormalities have been found in approximately
50% to 70% of patients with aHUS,4,10 and a wide
variety of mutations are associated with the condition.4,8P
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Although gene mutations increase the risk of aHUS, they
may not be sufﬁcient to cause overt symptoms without
additional environmental triggers. These include
infections, pregnancy, certain medications, malignancy,
sepsis, bone marrow transplantation, and connective
tissue disorders.2,9,11 Consequently, genetic testing is
currently not useful for the acute diagnosis of aHUS
(eg, in the ICU setting), but it can provide diagnostic
conﬁrmation, prognostic value, and information on
long-term treatment. Furthermore, because of the severe
nature of the condition, the time delay in obtaining
genetic results is not consistent with the need for rapid
initiation of therapy. In the absence of any fast, speciﬁc
diagnostic tests for aHUS, the condition can only be
diagnosed after exclusion of TTP12 and related TMAs.
Previously, aHUS and TTP have been managed in the
same way because the conditions are difﬁcult to
differentiate and only one treatment option, plasma
therapy (plasma infusion or plasma exchange), was
available.1,4 The beneﬁts of plasma exchange, although
not evaluated in prospective studies, include the removal
of pathologic substances from the blood and the
replacement of deﬁcient plasma components.13
However, although plasma therapy has improved
outcomes considerably in TTP, reducing the mortality
rate from 90% to 10% to 20%,14 > 50% of patients with
aHUS proceed to end-stage renal disease or death
despite plasma therapy.8,12 Consequently, speciﬁc,
urgent, and interdisciplinary management is paramount
in the treatment of patients with aHUS because of both
the severity of the illness and the potential development
of irreversible complications of organ involvement.1
Eculizumab, approved in 2011, is the ﬁrst treatment for
aHUS with proven efﬁcacy and safety in prospective
clinical trials.6 This monoclonal antibody targets the
complement system by blocking the cleavage of C5,
avoiding the production of cleavage products C5a and
C5b15; evidence suggests that early initiation can
improve renal and nonrenal recovery.16,17
In many cases, the ICU is the only clinical environment
in which such specialized urgent care can be effectively
provided at any time. Based on our experience,
physicians in the ICU see an average of three patients
with TMA per year, many of whom are not diagnosed
at the time of admission. Although treatment guidelines
for aHUS are available for nephrology,14,18-20 there is
currently no consensus on the diagnosis or treatment
of aHUS for ICU specialists. This review aims to
summarize available data on the diagnosis and treatment
of aHUS in the ICU with the goal of enhancing the426 Contemporary Reviews in Critical Care Medicineunderstanding of aHUS diagnosis and outcomes in
patients managed in the ICU.
Research Design and Methods
The need for this article was identiﬁed by a
multidisciplinary multinational expert panel of
11 members (nine intensive care physicians and two
hematologists) who met in September 2015 to deﬁne
unmet needs and skill priorities for ICU clinicians
managing critically ill patients with aHUS and to
evaluate existing recommendations outside critical
care. A literature search was conducted in the
National Library of Medicine database (PubMed)
looking for articles published between January 2009
and March 2016, using the following search terms:
“atypical haemolytic uraemic syndrome” or “atypical
hemolytic uremic syndrome” or “diarrhoea negative
haemolytic uraemic syndrome” or “diarrhea negative
hemolytic uremic syndrome” or “aHUS” or “D-HUS,”
with search ﬁlters of “humans” and “English
language.” Additional relevant articles were also
included from Internet searches using the same search
terms. Articles were reviewed manually for relevance
by the authors; studies concerning both transplant
and native kidney patients with aHUS were permitted
in this study, as were systematic literature reviews and
specialist review articles. In total, 539 articles were
identiﬁed, of which 56 were considered relevant
(included diagnosis and/or treatment of adult patients
with aHUS).
Diagnosis of Patients With aHUS
Diagnosis of aHUS typically commences with the broad
diagnosis of TMA (Fig 2, Table 1)21-24 and implicates
the involvement of not only the ICU physician but
also other specialists, notably hematologists and
nephrologists. Clinical suspicion of a TMA is based
on clinical ﬁndings, including microangiopathic
hemolytic anemia, thrombocytopenia, low haptoglobin,
elevated lactate dehydrogenase, elevated reticulocytes,
fragmented red cells, and schistocytes on peripheral
blood smear. Acute kidney injury is common in
aHUS, but other organ involvement, including cardiac,
gastrointestinal, or neurological damage, may be present
and can dominate the clinical picture1,5,25-28 (Fig 2,
Table 1). Once suspicion of TMA has been established,
further investigations, including a full patient medical
and family history, are required to exclude other
potential causes of TMA, including TTP, STEC-HUS,
or TMA as a transient manifestation of another
condition (eg, malignancy, autoimmune disease) or[ 1 5 2 # 2 CHES T A UGU S T 2 0 1 7 ]
Repeat test after
24 hours if both
not present
TMA DIAGNOSIS CONFIRMATION
CLINICAL SUSPICION OF TMA*
EXCLUDE OTHER CAUSES OF TMA
DIC: prothromb in time and aPTT prolonged; fibrinogen low (or low-normal with infection);
D-dimers high; antithrombin and protein C low
Evans syndrome, S. pneumoniae HUS, Autoimmune hemolytic anemia: Positive Coombs test
Disseminated malignancy/bone marrow carcinosis
Drug use: heparin use, alcohol toxicity, ADP-receptor antagonists, GP IIb/IIIa inhibitors, calcineurin
inhibitors, mitomycin C, quinine etc.
Others**
Organ transplantation, including hematopoietic stem cell transplantation
If symptoms persist after treatment of one of the above mentioned causes of TMA, consider differential
diagnosis of aHUS, STEC-HUS or TTP
TMA DIFFERENTIAL DIAGNOSIS
TTP
ADAMTS13 activity < 10% ADAMTS13 activity > 10% Shiga-toxin/EHEC positivity
aHUS STEC-HUS
Family history of TMA and/or renal failure supports a diagnosis of aHUS or congenital TTP
Please consult a hematologist and/or nephrologist where appropriate
SCHISTOCYTES
HAPTOGLOBIN
COAGULATION
DIRECT ANTIGLOBULIN
(COOMBS) TEST
Negative
Tests within normal range
Reduction < N.V.
Presence of schistocytes in blood smear
(specify % and number/field)
GI
Abdominal pain
Nausea
Vomiting
Diarrhea
Diarrhea with blood
Organ damage (> 1) Thrombocytopenia
++
Microangiopathic
hemolysis
CNS
Confusion
Seizures
Stroke
Coma
RENAL
Oligoanuria
Oedema
sCr > N.V.
Proteinuria
Micro/Macrohematuria
OTHER
Fatigue/asthenia
Purpura/petechiae
Dyspnoea
Hypertension
Fever
PLT consumption
If two categories, repeat
test after 24 hours
If three categories, move to
TMA diagnosis confirmation
PLT < 150 ×109/L
or
PLT reduction > 25%
LDH > N.V.
or
Close to the limit of N.V.
(if Hb < N.V. check LDH)
Elevated reticulocytes
Figure 2 – Algorithm for the differential diagnosis of aHUS in the ICU.1,12,14,21-24 *If two categories of clinical ﬁndings are present (organ damage and/
or thrombocytopenia and/or microangiopathic hemolysis), repeat tests after 24 hours. If three categories of clinical ﬁndings are present, move to
TMA diagnosis conﬁrmation. **Includes acute viremia (CMV, HIV, or EBV), pregnancy-associated complications (HELLP or preeclampsia),
malignant hypertension, catastrophic antiphospholipid antibody syndrome, and severe systemic autoimmune diseases. This list is not exhaustive.
ADP ¼ adenosine diphosphate; aPTT¼ activated partial thromboplastin time; CNS ¼ central nervous system; DIC ¼ disseminated intravascular
coagulation; EHEC¼ enterohemorrhagic Escherichia coli; GI¼ gastrointestinal; GP¼ glycoprotein; Hb ¼ hemoglobin; LDH,¼ lactate dehydrogenase;
N.V. ¼ normal value; PLT ¼ platelet; sCr ¼ serum creatinine. See Figure 1 legend for expansion of other abbreviations.
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TABLE 1 ] Recommended Tests for the Differential Diagnosis of aHUS1,12,14,21-24
Identify TMA
Test Outcome in aHUS Alternative Diagnosis
Reticulocyte counts Increased
Free serum hemoglobin Increased
LDH Increased
Haptoglobin Decreased Often decreased in TMAs, normal in
DIC and sepsis
Schistocytes Present Can be present in all TMAs
Platelet count Decreased (most of the time) Can be reduced in all TMAs
Hemoglobin Decreased Can be decreased in all TMAs
Serum creatinine Increased (most of the time) Can be increased in all TMAs
Hematuria and proteinuria Present (most of the time) Can be present in all TMAs
Kidney biopsya Often arteriolar and/or glomerular intracapillary thrombosis if kidney
affected
Additional tests to perform to advise on other possible causes of TMA
Direct antiglobulin test (Coombs test) Negative Positive in autoimmune hemolytic
anemias, Evans syndrome, and
pneumococcal HUS
Fibrinogen Normal Reduced ﬁbrinogen and elevated
ﬁbrinogen degradation products
in DIC
aPTT, PT Normal Prolonged in DIC
Plasma coagulation tests Normal Reduced in DIC
D-dimer Normal (can be elevated) Elevated D-dimer in DIC or TMA
Liver enzyme levels Normal (can be elevated if liver is
involved)
Elevated in HELLP syndrome
Viral infections, including HIV, HBV, HCV,
and H1N1
Can be a precipitant of aHUS Known external precipitant of TMA
Pregnancy test (where appropriate) Pregnancy-triggered TMA caused
by aHUS usually presents in late
pregnancy or postpartum
Pregnancy-triggered TMA caused
by TTP usually presents during
pregnancy
Antibody testing, including antinuclear
antibody, lupus anticoagulant, and
antiphospholipid antibodies
Negative Positive in systemic diseases, such
as SLE, CAPS; 30% of TTP have
positive antinuclear antibodies
Rule out TTP and STEC-HUS
STEC infection: fecal sample or rectal swab
test for Escherichia coli and/or PCR for
Shiga toxin, and serology of LPS of
common Shiga toxin-producing strains
Negative Positive in STEC-HUS
ADAMTS13 > 10% activity < 10% activity in TTP
This is not an exhaustive list, but a suggestion. Further tests for conditions that can mimic TMA, such as malaria, babesiosis, and vitamin deﬁciency,
may be warranted. ADAMTS13 ¼ a disintegrin and metalloproteinase with thrombospondin motifs 13; aHUS ¼ atypical hemolytic uremic syndrome;
aPTT ¼ activated partial thromboplastin time; CAPS ¼ cryopyrin-associated autoinﬂammatory syndrome; DIC ¼ disseminated intravascular coagulation;
HBV ¼ hepatitis B virus; HCV ¼ hepatitis C virus; HELLP ¼ hemolysis, elevated liver enzymes, low platelet count; HUS ¼ hemolytic uremic syndrome;
LDH ¼ lactate dehydrogenase; LPS ¼ lipopolysaccharide; PCR ¼ polymerase chain reaction; PT ¼ prothrombin time; SLE ¼ systemic lupus erythematosus;
STEC ¼ Shiga toxin-producing Escherichia coli; STEC-HUS ¼ Shiga toxin-associated hemolytic uremic syndrome; TMA ¼ thrombotic microangiopathy;
TTP ¼ thrombotic thrombocytopenic purpura.
aKidney biopsies are rarely performed because little information can be obtained above that from laboratory results; kidney biopsy in critically ill patients
with low platelet counts should not be performed because of bleeding risk.adverse drug effect; however, identiﬁcation of one of
these modulating factors does not preclude development
of aHUS in individuals with a genetic predisposition.428 Contemporary Reviews in Critical Care MedicineAdditionally, an HIV test and a pregnancy test in
women of child-bearing age should be performed to
account for these potential triggers.21[ 1 5 2 # 2 CHES T A UGU S T 2 0 1 7 ]
Differential Diagnosis
Distinguishing aHUS From TTP: ADAMTS13
Activity: The most critical and urgent differential
diagnosis is to differentiate TTP from aHUS because
of the urgency of speciﬁc treatment. Testing for
ADAMTS13 (a disintegrin and metalloproteinase with
thrombospondin motifs 13) activity is recommended to
differentiate between TTP and aHUS,27 and sampling
must take place prior to administration of plasma
therapy. ADAMTS13 deﬁciency is characteristic of TTP,
with levels < 10% widely considered to be diagnostic for
the condition.12,14,27,29-32 ADAMTS13, also known as
von Wilbrand Factor cleavage protease, acts by cleavage
of von Wilbrand Factor into smaller, less thrombotic
fragments, thereby reducing platelet aggregation.
Conversely, in TTP, reduced activity of ADAMTS13
results in platelet hyperadhesiveness and clumping
within the microvasculature.27,33
Somewhat reduced ADAMTS13 activity levels
(> 10% of normal) may also occur in aHUS, but such
levels are sufﬁcient to exclude TTP. Although results
from the ADAMTS13 assay are typically available within
a few hours when the assay is established in the local
laboratory, they may take some additional days when the
sample has to be shipped, meaning that treatment
decisions may need to be made prior to receiving the
results of the test. If ADAMTS13 tests are not available
within a few hours, a diagnostic algorithm developed by
Coppo et al,34 in which TTP is suggested by low platelet
count (< 30  109/L), mildly elevated serum creatinine
(# 200 mmol/L), and detectable antinuclear antibodies,
could help form an initial differential diagnosis. In the
interim, until TTP has been excluded, patients should
receive plasma exchange.
Organ Involvement: The presence of associated organ
involvement may be included within the diagnostic
workup to provide evidence for differentiation of aHUS
from TTP, but it is not conclusive. Renal impairment is
the most common complication in aHUS (Fig 3), but
renal function may be preserved in up to 20% of cases.
Acute kidney injury may be seen in TTP, but it is
typically reversible with therapy.35 The need for renal
support, such as hemodialysis, is not a common feature
of TTP, but it can be seen in progressive disease with
multiorgan involvement.
Neurologic signs (eg, confusion, focal cerebral
abnormalities, seizures) and cardiovascular signs (eg,
cardiomyopathy, myocardial infarction, myocarditis,
heart failure) occur in 10% to 48% and 10%of aHUS cases,chestjournal.orgrespectively9; however, these signs tend to be more
frequent in TTP.14,36 Tsai37 reported that complications
of abnormal vascular permeability (including brain
edema, pleural or pericardial effusions, pulmonary edema
from oliguria or cardiac insufﬁciency, and ascites) may be
used to differentiate TTP from aHUS because they are
thought to occur rarely in TTP without comorbidity.
aHUS is also occasionally associated with large artery
obstruction.38 Arterial hypertension may be present,
whereas pulmonary involvement is frequent in untreated
aHUS but rarely associated with other TMAs.27
Complement Protein-Level Testing: Complement
factor testing for complement component 3 (C3) and
complement component 4, complement factor H,
complement factor I, and antibodies against complement
components can detect protein deﬁciencies caused by
genetic mutations but cannot differentiate between
normal protein and normal levels of functionally
ineffective protein.31 Complement component 4 levels are
usually normal, but C3 levels are low (normal range,
88-252 mg/dL in men and 88-206 mg/dL in women39) in
up to 40% of patients with aHUS.26,40 Many functional
complement tests are very sensitive to preanalytical
errors. Therefore, complement testing may help to
conﬁrm suspected aHUS, but it is not useful as a
diagnostic test by itself.
Genetic Testing: Genetic abnormalities in the
complement system proteins have been documented,41
and assessment of these mutations may be used to
conﬁrm a diagnosis. Mutations in complement factor
H account for approximately 25% of aHUS cases,
membrane cofactor protein for approximately 10%,
complement factor I for 5% to 10%, and thrombomodulin
for up to 5% of cases42; however, no knownmutations are
identiﬁed in 30% to 50% of patients.4,10 Other genetic
variants include gain-of-function mutations in the
genes coding for complement factor B and C3, and
anticomplement factor H antibodies associated with
homozygous complement factor H-related 1-3
deletion.4,8 The parameters associated with clinical
aHUS onset are yet to be wholly elucidated. The current
hypothesis is a two-hit model: (1) preexisting genetic
susceptibility factors that are capable of stimulating
endothelial cell activation/damage and/or platelet
aggregation; and (2) modulating factors, encompassing a
variety of conditions that can be infectious, inﬂammatory,
or related to pregnancy, drugs, or stress and are linked
epidemiologically to both TTP and aHUS.27 Mutations
confer a genetic predisposition; therefore, although a
positive result is compatible with the diagnosis, a negative429
CNS:
Irritability, drowsiness, convulsions,
encephalopathy, diplopia, cortical
blindness, hemiparesis or
hemiplegia, stupor and coma
Cardiovascular:
Cardiomyopathy, myocardial
infarction, myocarditis and
heart failure
Skin:
Purpuric rash
GI:
Diarrhea, abdominal colics,
constipation, abdominal distension,
strictures, occlusions, intestinal
perforations, pancreatitis,
intestinal bleeding, hepatic cytolysis
Pulmonary:
Pulmonary hypertension,
pulmonary hemorrhage,
pulmonary edema
Renal:
Renal impairment, end stage renal disease
Skeletal muscle:
Rhabdomyolysis
Figure 3 – Frequency of organ involvement in atypical hemolytic uremic syndrome.9 See Figure 2 legend for expansion of abbreviations.result does not necessarily exclude aHUS. Additionally,
the results from such tests may take weeks, which is not
compatible with the urgent care setting of the ICU, where
rapid treatment decisions and administration of urgent
therapy are necessities.
Distinguishing aHUS From STEC-HUS and
Pneumococcal HUS
Culture-based assays (serology or polymerase chain
reaction) for Shiga toxin-producing Escherichia coli
(STEC), using a stool or rectal swab, in patients with
diarrhea can diagnose STEC-HUS and clearly
differentiate it from aHUS. Although E coli is not the
only source of Shiga toxin, STEC-HUS, previously
referred to as typical HUS or diarrhea-positive HUS, is
the most commonly used terminology today and is used
here to refer to this subset of HUS. The presence of
diarrhea alone has been used in the past to differentiate
between the conditions; however, this cannot be relied
on because up to one-third of aHUS cases also involve
diarrhea; therefore, so the presence of Shiga toxin must
be analyzed in patients with diarrhea.27 Pneumococcal
HUS is linked to the evidence of invasive pneumococcal
infection. Bacterial culture from sterile bodily ﬂuids is
required for conﬁrmation of pneumococcal infection,
and pneumococcal HUS is—in contrast with aHUS and
TTP—often associated with a positive Coombs test.21
Further Tests to Consider in the Workup of a Patient
Presenting With TMA
Patients presenting with TMA may require further
testing to rule out additional associated conditions.
Disseminated intravascular coagulopathy and sepsis
may present with TMA features but can be ruled out by
measuring coagulation parameters, which are all normal430 Contemporary Reviews in Critical Care Medicinein aHUS and TTP.14 Pregnancy can result in
complications of TMAs; TMA often leads to fetal death,
and TMA therapy may have an inﬂuence on the fetus.
Therefore, a pregnancy test should be performed in
women of childbearing age.22 Viral infections,
including HIV, hepatitis B virus, hepatitis C virus,
cytomegalovirus, and Epstein-Barr virus, can also cause
TMA and therefore must be investigated.1,22 Serology
tests, such as antinuclear antibodies and anti-DNA-
antibodies to neutrophil cytoplasmic antigens, must be
considered to rule out systemic diseases,1 and basal
organ testing, including a brain and lung CT scan,
troponin levels, blood glucose levels, and serum lipase
levels, is also recommended.22 Although a negative
direct antiglobulin test (Coombs test) can conﬁrm
TMA, a positive result may be indicative of autoimmune
hemolytic anemia, Evans syndrome (when in
conjunction with immune-mediated thrombocytopenia),
or pneumococcal HUS. A full medical history should be
acquired to determine underlying conditions, such as
malignancies and drug- or medication-associated
TMAs,1,22 for example heparin-induced thrombocyto-
penia.43 Family history of TMA or renal injury should
also be evaluated considering the important genetic
component of aHUS.
Diagnosing aHUS in the ICU Setting
Data on the clinical presentation and diagnosis of aHUS,
particularly in the ICU setting, are limited by the small
number of patients with this condition reported in the
ICU literature.31 Furthermore, ﬁndings relating to aHUS
are mostly published in nephrology and hematology
journals, with limited reach to the ICU specialist. An
industry-supported global aHUS registry was initiated in
2012, and data on the baseline demographics and[ 1 5 2 # 2 CHES T A UGU S T 2 0 1 7 ]
clinical characteristics of 516 patients with aHUS were
recently published.44
A review of the available case studies relevant to the ICU
setting revealed that the initial diagnostic workup was
similar for all patients, regardless of the presenting
symptoms. It is notable that a variety of approaches were
taken for progression beyond the TMA diagnosis, with
most patients receiving initial plasma exchange while
undergoing further investigations, including
ADAMTS13 activity, Shiga toxin testing, kidney biopsy
if feasible in critically ill patients, and genetic screening.
Together, information from these case studies can
inform an appropriate workup relevant to patients
presenting with aHUS symptoms within the ICU. A
summary of the key considerations for the differential
diagnosis of aHUS in the ICU setting is presented in
Table 2.Treatment of Patients With aHUS in the ICU
Knowing the standard of care for patients with aHUS,
based on available guidelines and expert suggestions on
best practice in the treatment of critically ill patients
with aHUS, is a skill we consider necessary within the
ICU. No published guidelines or recommendations
focus on the management of patients in the ICU;
however, there are no differences in treatment
requirements between settings, and published treatment
guidelines from other clinical settings apply.TABLE 2 ] Key Considerations for Differential Diagnosis
of aHUS in the ICU
1. Microangiopathic hemolytic anemia,
thrombocytopenia, and organ impairment should be
recognized as being suggestive of TMA.
2. A full medical history should be taken to exclude or
identify other causes (eg, previous TMA episodes,
pregnancy, prior malignancies, drug use).
3. Disseminated intravascular coagulation and sepsis
should be ruled out by clinical picture, microbiologic
testing, and assessment of coagulation screen.
4. TTP and STEC-HUS should be ruled out with
ADAMTS13 activity (before initiation of plasma
therapy) and Shiga toxin tests; if ADAMTS13 activity
test is not available, the Coppo algorithm31 to assess
serum creatinine and platelet count may be
considered.
5. If TMA persists on speciﬁc treatment of associated
condition (Fig 1), differential diagnosis for aHUS
should be considered.
See Table 1 legend for expansion of abbreviations.
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The critical nature of acute TMA means that a high
proportion of patients may be admitted to the ICU at
presentation. Because of the severity of the progression of
aHUS and other TMAs, a suspected diagnosis should be
treated as a medical emergency, and initial supportive
measures should be introduced with urgency. The British
Committee for Standards in Haematology guidelines14
suggest that appropriate treatment should be initiated
within 4 to 8 h from diagnosis because delays are
associated with increased morbidity and mortality.
Although plasma exchange has greatly improved the
survival of patients with TTP,12 it is not considered the
most effective therapy for aHUS because most patients
will die or require long-term renal replacement therapy
despite this treatment.4,12,40 However, because of the
difﬁculty in differentiating between aHUS and TTP,
initiation of plasma exchange is often necessary while
laboratory results are being determined.45 Exceptions
include patients with metastatic cancer with bone marrow
involvement for which plasma exchange would not
improve the situation. Plasma exchange requires careful
monitoring of organ function, platelet counts, and the
presence of infections, which can arise from central venous
lines and other sources related to medical interventions.
Platelet concentrates should be avoided during initial
therapy because theymay aggravate platelet aggregation.22Speciﬁc Management of aHUS
Once ADAMTS13 is proven detectable (> 10% activity),
the probability of a diagnosis of aHUS is high, and more
speciﬁc therapy can be applied. This can be conﬁrmed
with a negative test for STEC, once laboratory results
have been received. Treatment options for aHUS were
limited to plasma exchange, dialysis for renal failure, and
kidney transplantation until 2011, when eculizumab, a
recombinant, humanized, monoclonal antibody was
approved for use in patients with aHUS.12,45 Eculizumab
selectively targets and inhibits the terminal complement
protein C5, thereby inhibiting the terminal complement
activation.46
Eculizumab has been demonstrated to be effective and
well tolerated in four prospective phase II trials in
patients with aHUS.46-49 These trials were however not
carried out in the critical care setting. In these trials,
terminal complement inhibition with eculizumab was
associated with inhibition of further TMA progression,
increased platelet count, and signiﬁcant improvement in
renal function, including discontinuation of dialysis in431
TABLE 3 ] Recommendations for Management of Adult
Patients With Suspected aHUS in the ICU
1. Obtain adequate diagnostic samples before plasma
therapy.
2. Make use of multidisciplinary care, including
nephrologists and hematologists.
3. Initiate plasma therapy within 4-8 h of admission or
diagnosis of TMA. For patients with an initial
presentation of TMA, switch to eculizumab as soon as a
diagnosis of aHUS is conﬁrmed (ADAMTS13 >
10% and STEC negative); for patients with a history of
previous aHUS, initiate eculizumab immediately on
admission to the ICU.
4. Careful ICU monitoring should be offered because
organ dysfunction may appear or worsen until
remission.
5. Because of the increased risk of Neisseria meningitidis
infection with eculizumab treatment, patients should
be vaccinated against serotypes A, C, Y, and W135 and
subtype B 2 weeks before eculizumab is initiated;
unvaccinated individuals should receive prophylactic
antibiotics on eculizumab initiation until at least
2 weeks after N meningitidis vaccination (please refer
to country-speciﬁc guidelines).
See Table 1 legend for expansion of abbreviations.80% of patients on dialysis at initiation of treatment and
prevention of recurrence after transplantation.6 Based
on these results, eculizumab was included in a 2015
update to the clinical guidelines1 and in an international
consensus for the treatment of aHUS in children in
2016.19 In addition, a number of reviews on the
management of patients with aHUS recommend the use
of eculizumab.14,20,21,31,45,50,51 However, eculizumab is
contraindicated in patients with unresolved neisserial
infection (eg, Neisseria meningitidis) and in unvacci-
nated individuals because of the role of terminal com-
plement in the prevention of neisserial infection, unless
the beneﬁts of treatment outweigh the risks of con-
tracting the infection.52 Vaccination against N menin-
gitidis serotypes A, C, Y, and W135 and meningococcus
type B should be administered at least 2 weeks prior to
initiation of eculizumab. If eculizumab treatment needs
to be initiated immediately in a critically ill patient,
prophylactic antibiotics should be given at the start of
therapy and maintained for a minimum of 2 weeks53 or
as speciﬁed in individual country guidelines.
Management should also include supportive measures
aimed at managing the risks and consequences of
aHUS, such as hypertension, anemia, thrombocyto-
penia, acute renal failure, and infections, particularly in
patients not receiving speciﬁc targeted treatment (eg,
eculizumab). Hypertension is common in patients pre-
senting with aHUS and should be managed with
appropriate medications (angiotensin converting
enzyme inhibitors or angiotensin receptor blockers),
and red blood cell transfusion may be considered for
patients with anemia, noting that platelet infusions are
contraindicated unless the patient is bleeding or at high
risk of hemorrhage (ie, at-risk surgical procedure) or
severely thrombocytopenic (platelet count < 30,000/
mm3). Because of the risk of relapse triggered by
infections, physicians should be vigilant for signs of
infection, initiating appropriate treatment where
necessary.1,3
Recommendations for Standard of Care for Patients
With aHUS in the ICU
Using published recommendations1 and expert opinions
of our author group, recommendations for the standard
of care for adult patients with aHUS in the ICU are
outlined in Table 3.
Outcomes of Critically Ill Patients With aHUS
Data regarding the outcomes of adult patients with
aHUS are sparse because of the rarity of the disorder,432 Contemporary Reviews in Critical Care Medicineand data relating to the treatment of such patients in the
ICU are rarer still. However, existing studies agree that
the prognosis of patients with aHUS is poor, with
approximately 50% of patients requiring dialysis,
suffering permanent kidney damage, or dying within
1 year of ﬁrst occurrence despite plasma therapy.4,10,54
In an Italian cohort, mortality after the ﬁrst episode was
2% in adults; this was markedly lower than the
12% mortality rate reported in children in the same
study. Furthermore, 32% of survivors never recovered
renal function.10 Despite plasma therapy, at 3 to 5 years
after onset, 67% of adults with aHUS had either died or
reached end-stage renal failure.10
Kidney transplantation, although cited as a treatment
option for aHUS, was, in fact, rarely considered because
of an overall risk of recurrence after transplantation of
50%, with a high risk of graft rejection (up to 100%) in
those with recurrence.3 The risk of posttransplant
recurrence varies according to the genetic mutation
present and ranges from 0% to 30% in patients with
membrane cofactor protein mutation, 40% to 70% with
C3 mutation, 45% to 80% with complement factor I
mutation, 75% to 90% with complement factor H
mutation, and up to 100% with complement factor B
mutation.3,10,17,55 Because of the high risk of graft
rejection, living-donor transplantation is not recom-
mended, particularly from living relations because of the[ 1 5 2 # 2 CHES T A UGU S T 2 0 1 7 ]
increased risk of the donor subsequently developing
aHUS.3
Since the approval of eculizumab, outcomes of patients
with aHUS have improved signiﬁcantly, causing a
paradigm shift in the management of these patients.19,49
Notably, 80% of patients on dialysis at baseline could
discontinue dialysis with eculizumab.21,47 A 2-year
extension of a phase II study with eculizumab found that
hematologic normalization was achieved by 13 of 17
patients after 26 weeks and by 15 patients at both years
1 and 2. In a retrospective study of 19 cases of aHUS in
adults, all with acute kidney injury, nine had normal
kidney function after 3 months’ treatment with
eculizumab.56
Conclusions
To our knowledge, this review is the ﬁrst of its kind to
outline the standard of care in critically ill adult patients
with aHUS in the ICU. aHUS is deﬁned by
thrombocytopenia, nonimmune hemolytic anemia, and
acute kidney injury, and often presents with associated
organ dysfunction. Although TTP is fairly well
recognized by critical care specialists, aHUS remains a
diagnostic challenge because of the rarity of the disease.
Because there are no speciﬁc tests, and aHUS is
diagnosed by exclusion, diagnosis should be oriented
toward aHUS if disseminated intravascular coagulation
is ruled out, STEC test is negative, and plasma activity of
ADAMTS13 is > 10%. For optimal patient outcomes,
early recognition and appropriate treatment are critical
to reduce the risk of irreversible organ damage or death.
This review suggests initiating plasma therapy within
4 to 8 h of TMA diagnosis and switching to eculizumab
treatment as early as possible after a conﬁrmed
aHUS diagnosis (ADAMTS13 > 10% and a negative
STEC test).
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